Evaluation of Outcomes From Treatment of Benign or Malignant Gastrointestinal Diseases

Gastrointestinal Disease Clinical Trial

Official title:

Evaluation of Outcomes From Treatment of Benign or Malignant Gastrointestinal Diseases

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05115877
• Other study ID #: 031.HPB.2020.R
• Status: Enrolling by invitation
• Start date: January 7, 2021
• Est. completion date: May 17, 2024

Study information

• Verified date: April 2023
• Source: Methodist Health System
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will be a retrospective, registry study collecting data of patients who were diagnosed with benign or malignant gastrointestinal diseases. Data will be collected from patient's chart retrospectively once the patients have completed proper treatment follow up with physicians' practice.

Description:

It is reported in the literature that the treatment of any gastrointestinal disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with gastrointestinal cancer continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. The goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality and morbidity. The main aim of this study is to evaluate and compare the outcomes from our treatment of benign or malignant gastrointestinal diseases through medical chart review. There is a need to understand and improve the current diagnosis and treatment algorithm for gastrointestinal pathologies. Continued evaluation and study is imperative to ensure that national guidelines are improving to enhance patient cure and/or recovery.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 1000
• Est. completion date: May 17, 2024
• Est. primary completion date: May 17, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients diagnosed and treated for gastrointestinal diseases, benign or malignant from 2005 to 2030.
• Age =18 years

Exclusion Criteria:

• Patients that are not diagnosed with or treated for gastrointestinal diseases
• Age <18 years

Related Conditions & MeSH terms

• Digestive System Diseases
• Gastrointestinal Disease
• Gastrointestinal Diseases

Locations

Country	Name	City	State
United States	Methodist Richardson Medical Center	Richardson	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Methodist Health System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	from day of diagnosis or procedure to death date	Jan 2005 - Jan 2030
Primary	Overall symptom	Difficulty swallowing, Heartburn, Regurgitation, Chest pain, Weight Loss, Quality of life	Jan 2005 - Jan 2030
Primary	Mortality	death or life	Jan 2005 - Jan 2030
Primary	Morbidity	yes or no to individual disease	Jan 2005 - Jan 2030